Tuesday, November 03, 2015 9:08:17 AM
According to the National Institute of Mental Health (NIMH), major depression is one of the most common mental disorders in the United States. In 2013, an estimated 15.7 million individuals aged 18 or over – roughly 6.7 percent of all U.S. adults – had at least one major depressive episode. For these individuals, finding relief can be difficult. The American Academy of Family Physicians reports that up to two-thirds of all patients diagnosed with major unipolar depression will not respond to the first medication prescribed. If the second form of treatment also fails to produce a significant clinical improvement, the patient’s depression may be considered resistant to treatment. At this point, individuals have traditionally had extremely limited options for conquering this debilitating condition.
VistaGen Therapeutics, Inc. (OTCQB: VSTA), through the development of AV-101, is addressing this underserved indication. Earlier today, the company announced that it has taken a major step toward the eventual commercialization of its innovative drug candidate by dosing the first patient in its ongoing phase IIa study of AV-101 for treatment-resistant major depressive disorder (MDD). The study, which is being funded by the NIMH, is expected to enroll between 24 and 28 adult patients in order to evaluate the efficacy and safety of a single oral dose of AV-101 administered once daily for two weeks.
“We are pleased to have achieved this important milestone, notably advancing our AV-101 clinical development program, and we look forward to working closely with the esteemed leadership team at the NIMH,” Shawn Singh, chief executive officer of VistaGen, stated in a news release. “We believe that AV-101’s differentiated mechanism of action, oral availability, strong preclinical efficacy and excellent clinical safety profile support AV-101 as a potentially transformative treatment for millions of patients with MDD who are inadequately served by standard antidepressant therapies.”
In previous clinical testing, AV-101 has exhibited a host of sustained anti-depressant effects that exceed the effectiveness of currently available medications in the multi-billion dollar global antidepressant market – including serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). While SSRIs and SNRIs must be taken for several weeks before patients experience significant therapeutic benefits, AV-101 has demonstrated robust and rapid antidepressant effects similar to the benefits of ketamine without the high potential for abuse and psychosis-like behavioral side effects.
With its phase IIa study now underway, VistaGen expects top-line data in the first half of 2017. For prospective shareholders, the company’s progress toward the commercialization of its groundbreaking drug candidate makes it an intriguing investment opportunity in the coming months. Look for VistaGen to continue to benefit from its collaboration with the NIMH as it progresses toward a potentially transformative advancement in the treatment of MDD.
For more information on the company, visit www.vistagen.com
Recent VTGN News
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
- Vistagen to Present at Stifel 2024 Virtual CNS Days • Business Wire • 03/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/01/2024 05:15:07 AM
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:18:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:03 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:52:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:33:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:25:18 PM
- Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update • Business Wire • 02/13/2024 09:20:00 PM
- Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024 • Business Wire • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:17:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:09:52 PM
- Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain • Business Wire • 12/27/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:44:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:42:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM